Beyond conventional antibiotics — New directions for combination products to combat biofilm

Advanced Drug Delivery Reviews

Volumn 112, Issue , 2017, Pages 48-60

  Bayramov, Danir Fanisovich ^a   Neff, Jennifer Ann ^a  

^a Allvivo Vascular Inc   (United States)

Author keywords

Antibiotic resistance; Antimicrobial; Antimicrobial peptides; Compartment model; Local drug delivery; Medical device coatings

Indexed keywords

ANTIBIOTICS; BIOFILMS; MICROORGANISMS; PEPTIDES;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL; ANTIMICROBIAL PEPTIDE; COMPARTMENT MODEL; LOCAL DRUG DELIVERY; MEDICAL DEVICES;

BIOMEDICAL EQUIPMENT;

ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

BACTERIAL STRAIN; BIOFILM; DEVICE INFECTION; DRUG CHOICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; INFECTION RISK; MATERIAL COATING; MEDICAL DEVICE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REVIEW; RISK REDUCTION; ANIMAL; DEVICES; DRUG EFFECTS; HUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; BIOFILMS; DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; HUMANS;

EID: 84994131120     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.07.010     Document Type: Review

References (194)

1. Wu, P., Grainger, D.W., Drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 27 (2006), 2450–2467.
2. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., Ray, S.M., Thompson, D.L., Wilson, L.E., Fridkin, S.K., I. Emerging Infections Program Healthcare-Associated, T. Antimicrobial Use Prevalence Survey, Multistate point-prevalence survey of health care-associated infections. N. Engl. J. Med. 370 (2014), 1198–1208.
3. S. American Thoracic, A. Infectious Diseases Society of, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 171 (2005), 388–416.
4. Anderson, D.J., Kirkland, K.B., Kaye, K.S., Thacker, P.A. II, Kanafani, Z.A., Auten, G., Sexton, D.J., Underresourced hospital infection control and prevention programs: penny wise, pound foolish?. Infect. Control Hosp. Epidemiol. 28 (2007), 767–773.
5. Hidron, A.I., Edwards, J.R., Patel, J., Horan, T.C., Sievert, D.M., Pollock, D.A., Fridkin, S.K., T. National Healthcare Safety Network, F. Participating National Healthcare Safety Network, NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect. Control Hosp. Epidemiol. 29 (2008), 996–1011.
6. Darouiche, R.O., Device-associated infections: a macroproblem that starts with microadherence. Clin. Infect. Dis. 33 (2001), 1567–1572.
7. Schierholz, J.M., Beuth, J., Implant infections: a haven for opportunistic bacteria. J. Hosp. Infect. 49 (2001), 87–93.
8. James, G.A., Swogger, E., Wolcott, R., Pulcini, E., Secor, P., Sestrich, J., Costerton, J.W., Stewart, P.S., Biofilms in chronic wounds. Wound Repair Regen. 16 (2008), 37–44.
9. Zhao, G., Usui, M.L., Lippman, S.I., James, G.A., Stewart, P.S., Fleckman, P., Olerud, J.E., Biofilms and inflammation in chronic wounds. Adv. Wound Care 2 (2013), 389–399.
10. Zhao, G., Usui, M.L., Underwood, R.A., Singh, P.K., James, G.A., Stewart, P.S., Fleckman, P., Olerud, J.E., Time course study of delayed wound healing in a biofilm-challenged diabetic mouse model. Wound Repair Regen. 20 (2012), 342–352.
11. Sen, C.K., Gordillo, G.M., Roy, S., Kirsner, R., Lambert, L., Hunt, T.K., Gottrup, F., Gurtner, G.C., Longaker, M.T., Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17 (2009), 763–771.
12. Ammons, M.C., Anti-biofilm strategies and the need for innovations in wound care. Recent Pat. Antiinfect. Drug Discov. 5 (2010), 10–17.
13. Darouiche, R.O., Antimicrobial approaches for preventing infections associated with surgical implants. Clin. Infect. Dis. 36 (2003), 1284–1289.
14. Schmidmaier, G., Lucke, M., Wildemann, B., Haas, N.P., Raschke, M., Prophylaxis and treatment of implant-related infections by antibiotic-coated implants: a review. Injury 37:Suppl. 2 (2006), S105–S112.
15. Uckay, I., Hoffmeyer, P., Lew, D., Pittet, D., Prevention of surgical site infections in orthopaedic surgery and bone trauma: state-of-the-art update. J. Hosp. Infect. 84 (2013), 5–12.
16. O'Meara, S., Al-Kurdi, D., Ologun, Y., Ovington, L.G., Martyn-St James, M., Richardson, R., Antibiotics and antiseptics for venous leg ulcers. Cochrane Database Syst. Rev., 12, 2013, CD003557.
17. O'Meara, S., Cullum, N., Majid, M., Sheldon, T., Systematic reviews of wound care management: (3) antimicrobial agents for chronic wounds; (4) diabetic foot ulceration. Health Technol. Assess. 4 (2000), 1–237.
18. Zilberman, M., Elsner, J.J., Antibiotic-eluting medical devices for various applications. J. Control. Release 130 (2008), 202–215.
19. Costerton, J.W., Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin. Orthop. Relat. Res., 2005, 7–11.
20. Harbarth, S., Samore, M.H., Antimicrobial resistance determinants and future control. Emerg. Infect. Dis. 11 (2005), 794–801.
21. May, J., Shannon, K., King, A., French, G., Glycopeptide tolerance in Staphylococcus aureus. J. Antimicrob. Chemother. 42 (1998), 189–197.
22. Richards, R.G., Moriarty, T.F., Miclau, T., McClellan, R.T., Grainger, D.W., Advances in biomaterials and surface technologies. J. Orthop. Trauma 26 (2012), 703–707.
23. Chen, M., Yu, Q., Sun, H., Novel strategies for the prevention and treatment of biofilm related infections. Int. J. Mol. Sci. 14 (2013), 18488–18501.
24. von Eiff, C., Kohnen, W., Becker, K., Jansen, B., Modern strategies in the prevention of implant-associated infections. Int. J. Artif. Organs 28 (2005), 1146–1156.
25. Hasan, J., Crawford, R.J., Ivanova, E.P., Antibacterial surfaces: the quest for a new generation of biomaterials. Trends Biotechnol. 31 (2013), 295–304.
26. Goodman, S.B., Yao, Z., Keeney, M., Yang, F., The future of biologic coatings for orthopaedic implants. Biomaterials 34 (2013), 3174–3183.
27. Boersma, R.S., Jie, K.S., Verbon, A., van Pampus, E.C., Schouten, H.C., Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann. Oncol. 19 (2008), 433–442.
28. Thornburg, C.D., Smith, P.B., Smithwick, M.L., Cotten, C.M., Benjamin, D.K. Jr., Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters. Thromb. Res. 122 (2008), 782–785.
29. Spellberg, B., Guidos, R., Gilbert, D., Bradley, J., Boucher, H.W., Scheld, W.M., Bartlett, J.G., Edwards, J. Jr., A. Infectious Diseases Society of, The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin. Infect. Dis. 46 (2008), 155–164.
30. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice, L.B., Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T., Monnet, D.L., Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18 (2012), 268–281.
31. Sanchez, C.J. Jr., Mende, K., Beckius, M.L., Akers, K.S., Romano, D.R., Wenke, J.C., Murray, C.K., Biofilm formation by clinical isolates and the implications in chronic infections. BMC Infect. Dis., 13, 2013, 47.
32. Francolini, I., Donelli, G., Prevention and control of biofilm-based medical-device-related infections. FEMS Immunol. Med. Microbiol. 59 (2010), 227–238.
33. Gbejuade, H.O., Lovering, A.M., Webb, J.C., The role of microbial biofilms in prosthetic joint infections. Acta Orthop. 86 (2015), 147–158.
34. McConoughey, S.J., Howlin, R., Granger, J.F., Manring, M.M., Calhoun, J.H., Shirtliff, M., Kathju, S., Stoodley, P., Biofilms in periprosthetic orthopedic infections. Future Microbiol 9 (2014), 987–1007.
35. Rhoads, D.D., Wolcott, R.D., Percival, S.L., Biofilms in wounds: management strategies. J. Wound Care 17 (2008), 502–508.
36. Arciola, C.R., Campoccia, D., Ravaioli, S., Montanaro, L., Polysaccharide intercellular adhesin in biofilm: structural and regulatory aspects. Front. Cell. Infect. Microbiol., 5, 2015, 7.
37. Donlan, R.M., Biofilms: microbial life on surfaces. Emerg. Infect. Dis. 8 (2002), 881–890.
38. Stewart, P.S., William Costerton, J., Antibiotic resistance of bacteria in biofilms. Lancet 358 (2001), 135–138.
39. Melchior, M.B., Fink-Gremmels, J., Gaastra, W., Extended antimicrobial susceptibility assay for Staphylococcus aureus isolates from bovine mastitis growing in biofilms. Vet. Microbiol. 125 (2007), 141–149.
40. Laverty, G., Alkawareek, M.Y., Gilmore, B.F., The in vitro susceptibility of biofilm forming medical device related pathogens to conventional antibiotics. Dataset Pap. Sci. 2014 (2014), 1–10.
41. Trafny, E.A., Susceptibility of adherent organisms from Pseudomonas aeruginosa and Staphylococcus aureus strains isolated from burn wounds to antimicrobial agents. Int. J. Antimicrob. Agents 10 (1998), 223–228.
42. Hengzhuang, W., Wu, H., Ciofu, O., Song, Z., Hoiby, N., In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob. Agents Chemother. 56 (2012), 2683–2690.
43. Campoccia, D., Montanaro, L., Arciola, C.R., A review of the biomaterials technologies for infection-resistant surfaces. Biomaterials 34 (2013), 8533–8554.
44. Arruebo, M., Vilaboa, N., Santamaria, J., Drug delivery from internally implanted biomedical devices used in traumatology and in orthopedic surgery. Expert Opin. Drug Deliv. 7 (2010), 589–603.
45. Guggenbichler, J.P., Assadian, O., Boeswald, M., Kramer, A., Incidence and clinical implication of nosocomial infections associated with implantable biomaterials — catheters, ventilator-associated pneumonia, urinary tract infections. GMS Krankenhhyg Interdiszip, 6, 2011 Doc18.
46. von Eiff, C., Jansen, B., Kohnen, W., Becker, K., Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs 65 (2005), 179–214.
47. Pascual, A., Pathogenesis of catheter-related infections: lessons for new designs. Clin. Microbiol. Infect. 8 (2002), 256–264.
48. Chiesa, R., Astore, D., Frigerio, S., Garriboli, L., Piccolo, G., Castellano, R., Scalamogna, M., Odero, A., Pirrelli, S., Biasi, G., Mingazzini, P., Biglioli, P., Polvani, G., Guarino, A., Agrifoglio, G., Tori, A., Spina, G., Vascular prosthetic graft infection: epidemiology, bacteriology, pathogenesis and treatment. Acta Chir. Belg. 102 (2002), 238–247.
49. Swain, T.W. III, Calligaro, K.D., Dougherty, M.D., Management of infected aortic prosthetic grafts. Vasc. Endovasc. Surg. 38 (2004), 75–82.
50. Wells, D.L., Allen, J.M., Ventriculoperitoneal shunt infections in adult patients. AACN Adv. Crit. Care 24 (2013), 6–12 quiz 13–14.
51. Rodriguez, D., Pigrau, C., Euba, G., Cobo, J., Garcia-Lechuz, J., Palomino, J., Riera, M., Del Toro, M.D., Granados, A., Ariza, X., Group, R., Acute haematogenous prosthetic joint infection: prospective evaluation of medical and surgical management. Clin. Microbiol. Infect. 16 (2010), 1789–1795.
52. Safdar, N., Crnich, C.J., Maki, D.G., The pathogenesis of ventilator-associated pneumonia: its relevance to developing effective strategies for prevention. Respir. Care 50 (2005), 725–739 discussion 739-741.
53. Zimmerli, W., Clinical presentation and treatment of orthopaedic implant-associated infection. J. Intern. Med. 276 (2014), 111–119.
54. Musella, M., Guido, A., Musella, S., Collagen tampons as aminoglycoside carriers to reduce postoperative infection rate in prosthetic repair of groin hernias. Eur. J. Surg. 167 (2001), 130–132.
55. Chia, C.L., Shelat, V.G., Low, W., George, S., Rao, J., The use of Collatamp G, local gentamicin-collagen sponge, in reducing wound infection. Int. Surg. 99 (2014), 565–570.
56. Ramritu, P., Halton, K., Collignon, P., Cook, D., Fraenkel, D., Battistutta, D., Whitby, M., Graves, N., A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. Am. J. Infect. Control 36 (2008), 104–117.
57. Raad, I., Darouiche, R., Dupuis, J., Abi-Said, D., Gabrielli, A., Hachem, R., Wall, M., Harris, R., Jones, J., Buzaid, A., Robertson, C., Shenaq, S., Curling, P., Burke, T., Ericsson, C., Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group. Ann. Intern. Med. 127 (1997), 267–274.
58. Hupcey, M.A., Ekins, S., Improving the drug selection and development process for combination devices. Drug Discov. Today 12 (2007), 844–852.
59. Brooks, B.D., Davidoff, S.N., Grainger, D.W., Brooks, A.E., Comparisons of release of several antibiotics from antimicrobial polymer-coated allograft bone void filler. Int. J. Biomed. Mater. Res. 1 (2013), 21–25.
60. Campoccia, D., Montanaro, L., Speziale, P., Arciola, C.R., Antibiotic-loaded biomaterials and the risks for the spread of antibiotic resistance following their prophylactic and therapeutic clinical use. Biomaterials 31 (2010), 6363–6377.
61. Hanna, H., Bahna, P., Reitzel, R., Dvorak, T., Chaiban, G., Hachem, R., Raad, I., Comparative in vitro efficacies and antimicrobial durabilities of novel antimicrobial central venous catheters. Antimicrob. Agents Chemother. 50 (2006), 3283–3288.
62. Davidoff, S.N., Sevy, J.O., Brooks, B.D., Grainger, D.W., Brooks, A.E., Evaluating antibiotic release profiles as a function of polymer coating formulation — biomed 2011. Biomed. Sci. Instrum. 47 (2011), 46–51.
63. Craig, W.A., Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26 (1998), 1–10 quiz 11-12.
64. Elek, S.D., Conen, P.E., The virulence of Staphylococcus pyogenes for man; a study of the problems of wound infection. Br. J. Exp. Pathol. 38 (1957), 573–586.
65. Levison, M.E., Pharmacodynamics of antimicrobial drugs. Infect. Dis. Clin. N. Am. 18 (2004), 451–465 vii.
66. French, G.L., Bactericidal agents in the treatment of MRSA infections—the potential role of daptomycin. J. Antimicrob. Chemother. 58 (2006), 1107–1117.
67. Pankey, G.A., Sabath, L.D., Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin. Infect. Dis. 38 (2004), 864–870.
68. Fux, C.A., Costerton, J.W., Stewart, P.S., Stoodley, P., Survival strategies of infectious biofilms. Trends Microbiol. 13 (2005), 34–40.
69. Brooks, B.D., Brooks, A.E., Therapeutic strategies to combat antibiotic resistance. Adv. Drug Deliv. Rev. 78 (2014), 14–27.
70. Derendorf, H., Meibohm, B., Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm. Res. 16 (1999), 176–185.
71. Mouton, J.W., Dudley, M.N., Cars, O., Derendorf, H., Drusano, G.L., Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55 (2005), 601–607.
72. Schuck, E.L., Derendorf, H., Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti-Infect. Ther. 3 (2005), 361–373.
73. Muller, M., dela Pena, A., Derendorf, H., Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob. Agents Chemother. 48 (2004), 1441–1453.
74. Liu, P., Muller, M., Derendorf, H., Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int. J. Antimicrob. Agents 19 (2002), 285–290.
75. Yang, C., Burt, H.M., Drug-eluting stents: factors governing local pharmacokinetics. Adv. Drug Deliv. Rev. 58 (2006), 402–411.
76. Bauer, L., Clinical pharmacokinetic equations and calculations. Applied Clinical Pharmacokinetics, 2008, McGraw-Hill, 34–37.
77. Gullberg, E., Cao, S., Berg, O.G., Ilback, C., Sandegren, L., Hughes, D., Andersson, D.I., Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog., 7, 2011, e1002158.
78. Rachid, S., Ohlsen, K., Witte, W., Hacker, J., Ziebuhr, W., Effect of subinhibitory antibiotic concentrations on polysaccharide intercellular adhesin expression in biofilm-forming Staphylococcus epidermidis. Antimicrob. Agents Chemother. 44 (2000), 3357–3363.
79. Hoffman, L.R., D'Argenio, D.A., MacCoss, M.J., Zhang, Z., Jones, R.A., Miller, S.I., Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436 (2005), 1171–1175.
80. Ahmed, N.A., Petersen, F.C., Scheie, A.A., AI-2/LuxS is involved in increased biofilm formation by Streptococcus intermedius in the presence of antibiotics. Antimicrob. Agents Chemother. 53 (2009), 4258–4263.
81. Neut, D., van de Belt, H., van Horn, J.R., van der Mei, H.C., Busscher, H.J., The effect of mixing on gentamicin release from polymethylmethacrylate bone cements. Acta Orthop. Scand. 74 (2003), 670–676.
82. Neut, D., van de Belt, H., van Horn, J.R., van der Mei, H.C., Busscher, H.J., Residual gentamicin-release from antibiotic-loaded polymethylmethacrylate beads after 5 years of implantation. Biomaterials 24 (2003), 1829–1831.
83. Schmolders, J., Hischebeth, G.T., Friedrich, M.J., Randau, T.M., Wimmer, M.D., Kohlhof, H., Molitor, E., Gravius, S., Evidence of MRSE on a gentamicin and vancomycin impregnated polymethyl-methacrylate (PMMA) bone cement spacer after two-stage exchange arthroplasty due to periprosthetic joint infection of the knee. BMC Infect. Dis., 14, 2014, 144.
84. Shi, M., Kretlow, J.D., Nguyen, A., Young, S., Scott Baggett, L., Wong, M.E., Kasper, F.K., Mikos, A.G., Antibiotic-releasing porous polymethylmethacrylate constructs for osseous space maintenance and infection control. Biomaterials 31 (2010), 4146–4156.
85. Helmus, M.N., Gibbons, D.F., Cebon, D., Biocompatibility: meeting a key functional requirement of next-generation medical devices. Toxicol. Pathol. 36 (2008), 70–80.
86. Morais, J.M., Papadimitrakopoulos, F., Burgess, D.J., Biomaterials/tissue interactions: possible solutions to overcome foreign body response. AAPS J. 12 (2010), 188–196.
87. Onuki, Y., Bhardwaj, U., Papadimitrakopoulos, F., Burgess, D.J., A review of the biocompatibility of implantable devices: current challenges to overcome foreign body response. J. Diabetes Sci. Technol. 2 (2008), 1003–1015.
88. Solanki, H.K., Thakkar, J.H., Jani, G.H., Recent advances in implantable drug delivery. Int. J. Pharm. Sci. Rev. Res. 4 (2010), 168–177.
89. Breitenbach, J., Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm. 54 (2002), 107–117.
90. Akers, M.J., Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 91 (2002), 2283–2300.
91. Wu, L., Janagam, D.R., Mandrell, T.D., Johnson, J.R., Lowe, T.L., Long-acting injectable hormonal dosage forms for contraception. Pharm. Res. 32 (2015), 2180–2191.
92. Gimeno, M., Pinczowski, P., Perez, M., Giorello, A., Martinez, M.A., Santamaria, J., Arruebo, M., Lujan, L., A controlled antibiotic release system to prevent orthopedic-implant associated infections: an in vitro study. Eur. J. Pharm. Biopharm. 96 (2015), 264–271.
93. Tcholakian, R.K., Raad, I.I., Durability of anti-infective effect of long-term silicone sheath catheters impregnated with antimicrobial agents. Antimicrob. Agents Chemother. 45 (2001), 1990–1993.
94. Benagiano, G., Gabelnick, H., Farris, M., Contraceptive devices: subcutaneous delivery systems. Expert Rev. Med. Devices 5 (2008), 623–637.
95. Kohnen, W., Kolbenschlag, C., Teske-Keiser, S., Jansen, B., Development of a long-lasting ventricular catheter impregnated with a combination of antibiotics. Biomaterials 24 (2003), 4865–4869.
96. Darouiche, R.O., Raad, I.I., Heard, S.O., Thornby, J.I., Wenker, O.C., Gabrielli, A., Berg, J., Khardori, N., Hanna, H., Hachem, R., Harris, R.L., Mayhall, G., A comparison of two antimicrobial-impregnated central venous catheters. Catheter study group. N. Engl. J. Med. 340 (1999), 1–8.
97. John, T., Rajpurkar, A., Smith, G., Fairfax, M., Triest, J., Antibiotic pretreatment of hydrogel ureteral stent. J. Endourol. 21 (2007), 1211–1216.
98. Schierholz, J.M., Steinhauser, H., Rump, A.F., Berkels, R., Pulverer, G., Controlled release of antibiotics from biomedical polyurethanes: morphological and structural features. Biomaterials 18 (1997), 839–844.
99. Berra, L., Curto, F., Li Bassi, G., Laquerriere, P., Baccarelli, A., Kolobow, T., Antibacterial-coated tracheal tubes cleaned with the mucus shaver: a novel method to retain long-term bactericidal activity of coated tracheal tubes. Intensive Care Med. 32 (2006), 888–893.
100. Morra, M., Cassinelli, C., Cascardo, G., Carpi, A., Fini, M., Giavaresi, G., Giardino, R., Adsorption of cationic antibacterial on collagen-coated titanium implant devices. Biomed. Pharmacother. 58 (2004), 418–422.
101. Popat, K.C., Eltgroth, M., Latempa, T.J., Grimes, C.A., Desai, T.A., Decreased Staphylococcus epidermis adhesion and increased osteoblast functionality on antibiotic-loaded titania nanotubes. Biomaterials 28 (2007), 4880–4888.
102. 2 nanotube arrays for peri-implant infections. J. Biomed. Mater. Res. A 100 (2012), 278–285.
103. Gulati, K., Ramakrishnan, S., Aw, M.S., Atkins, G.J., Findlay, D.M., Losic, D., Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion. Acta Biomater. 8 (2012), 449–456.
104. Yao, C., Webster, T.J., Prolonged antibiotic delivery from anodized nanotubular titanium using a co-precipitation drug loading method. J. Biomed. Mater. Res. B Appl. Biomater. 91 (2009), 587–595.
105. Costerton, J.W., Lewandowski, Z., Caldwell, D.E., Korber, D.R., Lappin-Scott, H.M., Microbial biofilms. Annu. Rev. Microbiol. 49 (1995), 711–745.
106. Kostakioti, M., Hadjifrangiskou, M., Hultgren, S.J., Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harb. Perspect. Med., 3, 2013, a010306.
107. Davey, M.E., O'Toole, G.A., Microbial biofilms: from ecology to molecular genetics. Microbiol. Mol. Biol. Rev. 64 (2000), 847–867.
108. Leon, C., Ruiz-Santana, S., Rello, J., de la Torre, M.V., Valles, J., Alvarez-Lerma, F., Sierra, R., Saavedra, P., Alvarez-Salgado, F., Cabana Study, G., Benefits of minocycline and rifampin-impregnated central venous catheters. A prospective, randomized, double-blind, controlled, multicenter trial. Intensive Care Med. 30 (2004), 1891–1899.
109. Wright, F., Heyland, D., Drover, J.W., McDonald, S., Zoutman, D., Antibiotic-coated central lines: do they work in the critical care setting?. Clin. Intensive Care 12 (2001), 21–28.
110. Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39 (2004), 309–317.
111. Lorente, L., Lecuona, M., Jimenez, A., Lorenzo, L., Santacreu, R., Ramos, S., Hurtado, E., Buitrago, M., Mora, M.L., Efficiency of chlorhexidine-silver sulfadiazine-impregnated venous catheters at subclavian sites. Am. J. Infect. Control 43 (2015), 711–714.
112. Wasiak, J., Cleland, H., Campbell, F., Dressings for superficial and partial thickness burns. Cochrane Database Syst. Rev., 2008, CD002106.
113. Meakins, J.L., Silver and new technology: dressings and devices. Surg. Infect. 10 (2009), 293–296.
114. Vestby, L.K., Nesse, L.L., Wound care antiseptics — performance differences against Staphylococcus aureus in biofilm. Acta Vet. Scand., 57, 2015, 22.
115. Phillips, P.L., Yang, Q., Davis, S., Sampson, E.M., Azeke, J.I., Hamad, A., Schultz, G.S., Antimicrobial dressing efficacy against mature Pseudomonas aeruginosa biofilm on porcine skin explants. Int. Wound J. 12 (2015), 469–483.
116. Poon, V.K., Burd, A., In vitro cytotoxity of silver: implication for clinical wound care. Burns 30 (2004), 140–147.
117. de Souza, L.B., de Aquino, S.G., de Souza, P.P., Hebling, J., Costa, C.A., Cytotoxic effects of different concentrations of chlorhexidine. Am. J. Dent. 20 (2007), 400–404.
118. Giangaspero, A., Sandri, L., Tossi, A., Amphipathic alpha helical antimicrobial peptides. Eur. J. Biochem. 268 (2001), 5589–5600.
119. Wang, G., Li, X., Wang, Z., APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44 (2016), D1087–D1093.
120. Koczulla, A.R., Bals, R., Antimicrobial peptides: current status and therapeutic potential. Drugs 63 (2003), 389–406.
121. Zasloff, M., Antimicrobial peptides of multicellular organisms. Nature 415 (2002), 389–395.
122. Reddy, K.V., Yedery, R.D., Aranha, C., Antimicrobial peptides: premises and promises. Int. J. Antimicrob. Agents 24 (2004), 536–547.
123. Hancock, R.E., Sahl, H.G., Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24 (2006), 1551–1557.
124. Laverty, G., Gorman, S.P., Gilmore, B.F., The potential of antimicrobial peptides as biocides. Int. J. Mol. Sci. 12 (2011), 6566–6596.
125. Batoni, G., Maisetta, G., Brancatisano, F.L., Esin, S., Campa, M., Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr. Med. Chem. 18 (2011), 256–279.
126. Park, S.C., Park, Y., Hahm, K.S., The role of antimicrobial peptides in preventing multidrug-resistant bacterial infections and biofilm formation. Int. J. Mol. Sci. 12 (2011), 5971–5992.
127. Xie, J., Gou, Y., Zhao, Q., Wang, K., Yang, X., Yan, J., Zhang, W., Zhang, B., Ma, C., Wang, R., Antimicrobial activities and membrane-active mechanism of CPF-C1 against multidrug-resistant bacteria, a novel antimicrobial peptide derived from skin secretions of the tetraploid frog Xenopus clivii. J. Pept. Sci. 20 (2014), 876–884.
128. Deslouches, B., Steckbeck, J.D., Craigo, J.K., Doi, Y., Burns, J.L., Montelaro, R.C., Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. Antimicrob. Agents Chemother. 59 (2015), 1329–1333.
129. Mohamed, M.F., Hammac, G.K., Guptill, L., Seleem, M.N., Antibacterial activity of novel cationic peptides against clinical isolates of multi-drug resistant Staphylococcus pseudintermedius from infected dogs. PLoS One, 9, 2014, e116259.
130. Afacan, N.J., Yeung, A.T., Pena, O.M., Hancock, R.E., Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr. Pharm. Des. 18 (2012), 807–819.
131. Lashua, L.P., Melvin, J.A., Deslouches, B., Pilewski, J.M., Montelaro, R.C., Bomberger, J.M., Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells. J. Antimicrob. Chemother., 2016.
132. Bayramov, D., Li, Z., Patel, E., Neff, J., Evaluating activities of novel antimicrobial peptides against Staphylococcus aureus biofilms. 10th World Biomaterials Congress, Montreal, Canada Front. Bioeng. Biotechnol, 2016.
133. Overhage, J., Campisano, A., Bains, M., Torfs, E.C., Rehm, B.H., Hancock, R.E., Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76 (2008), 4176–4182.
134. Nucleo, E., Steffanoni, L., Fugazza, G., Migliavacca, R., Giacobone, E., Navarra, A., Pagani, L., Landini, P., Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol., 9, 2009, 270.
135. Wang, Q., Sun, F.J., Liu, Y., Xiong, L.R., Xie, L.L., Xia, P.Y., Enhancement of biofilm formation by subinhibitory concentrations of macrolides in icaADBC-positive and -negative clinical isolates of Staphylococcus epidermidis. Antimicrob. Agents Chemother. 54 (2010), 2707–2711.
136. Peschel, A., How do bacteria resist human antimicrobial peptides?. Trends Microbiol. 10 (2002), 179–186.
137. Nizet, V., Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Mol. Biol. 8 (2006), 11–26.
138. LaRock, C.N., Nizet, V., Cationic antimicrobial peptide resistance mechanisms of streptococcal pathogens. Biochim. Biophys. Acta 1848 (2015), 3047–3054.
139. Yeaman, M.R., Yount, N.Y., Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55 (2003), 27–55.
140. Koprivnjak, T., Peschel, A., Bacterial resistance mechanisms against host defense peptides. Cell. Mol. Life Sci. 68 (2011), 2243–2254.
141. Peschel, A., Sahl, H.G., The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4 (2006), 529–536.
142. Fjell, C.D., Hiss, J.A., Hancock, R.E., Schneider, G., Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 11 (2012), 37–51.
143. Vlieghe, P., Lisowski, V., Martinez, J., Khrestchatisky, M., Synthetic therapeutic peptides: science and market. Drug Discov. Today 15 (2010), 40–56.
144. Helmerhorst, E.J., Reijnders, I.M., van ‘t Hof, W., Veerman, E.C., Amerongen, A.V.N., A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides. FEBS Lett. 449 (1999), 105–110.
145. Nguyen, L.T., Chau, J.K., Perry, N.A., de Boer, L., Zaat, S.A., Vogel, H.J., Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One, 5, 2010.
146. Pacor, S., Giangaspero, A., Bacac, M., Sava, G., Tossi, A., Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. J. Antimicrob. Chemother. 50 (2002), 339–348.
147. Fox, J.L., Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31 (2013), 379–382.
148. Niu, C.H., Chiu, Y.Y., FDA perspective on peptide formulation and stability issues. J. Pharm. Sci. 87 (1998), 1331–1334.
149. Rathore, N., Rajan, R.S., Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol. Prog. 24 (2008), 504–514.
150. Garrison, W.M., Reaction mechanisms in radiolysis of peptides, polypeptides, and proteins. Chem. Rev. 87 (1987), 381–398.
151. Huebsch, N., Gilbert, M., Healy, K.E., Analysis of sterilization protocols for peptide-modified hydrogels. J. Biomed. Mater. Res. B Appl. Biomater. 74 (2005), 440–447.
152. Wu, K.Y., Chiang, S.Y., Shih, W.C., Huang, C.C., Chen, M.F., Swenberg, J.A., The application of mass spectrometry in molecular dosimetry: ethylene oxide as an example. Mass Spectrom. Rev. 30 (2011), 733–756.
153. Chen, L., Sloey, C., Zhang, Z., Bondarenko, P.V., Kim, H., Ren, D., Kanapuram, S., Chemical modifications of therapeutic proteins induced by residual ethylene oxide. J. Pharm. Sci. 104 (2015), 731–739.
154. Rothen-Weinhold, A., Besseghir, K., De Zelicourt, Y., Gurny, R., Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue. J. Control. Release 52 (1998), 205–213.
155. Rothen-Weinhold, A., Besseghir, K., Vuaridel, E., Sublet, E., Oudry, N., Gurny, R., Stability studies of a somatostatin analogue in biodegradable implants. Int. J. Pharm. 178 (1999), 213–221.
156. Rothen-Weinhold, A., Oudry, N., Schwach-Abdellaoui, K., Frutiger-Hughes, S., Hughes, G.J., Jeannerat, D., Burger, U., Besseghir, K., Gurny, R., Formation of peptide impurities in polyester matrices during implant manufacturing. Eur. J. Pharm. Biopharm. 49 (2000), 253–257.
157. Deslouches, B., Phadke, S.M., Lazarevic, V., Cascio, M., Islam, K., Montelaro, R.C., Mietzner, T.A., De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob. Agents Chemother. 49 (2005), 316–322.
158. Liu, D., DeGrado, W.F., De novo design, synthesis, and characterization of antimicrobial beta-peptides. J. Am. Chem. Soc. 123 (2001), 7553–7559.
159. Loose, C., Jensen, K., Rigoutsos, I., Stephanopoulos, G., A linguistic model for the rational design of antimicrobial peptides. Nature 443 (2006), 867–869.
160. Muhle, S.A., Tam, J.P., Design of gram-negative selective antimicrobial peptides. Biochemistry 40 (2001), 5777–5785.
161. Deslouches, B., Islam, K., Craigo, J.K., Paranjape, S.M., Montelaro, R.C., Mietzner, T.A., Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob. Agents Chemother. 49 (2005), 3208–3216.
162. Deslouches, B., Gonzalez, I.A., DeAlmeida, D., Islam, K., Steele, C., Montelaro, R.C., Mietzner, T.A., De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J. Antimicrob. Chemother. 60 (2007), 669–672.
163. Novak, K.F., Diamond, W.J., Kirakodu, S., Peyyala, R., Anderson, K.W., Montelaro, R.C., Mietzner, T.A., Efficacy of the de novo-derived antimicrobial peptide WLBU2 against oral bacteria. Antimicrob. Agents Chemother. 51 (2007), 1837–1839.
164. Deslouches, B., Steckbeck, J.D., Craigo, J.K., Doi, Y., Mietzner, T.A., Montelaro, R.C., Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob. Agents Chemother. 57 (2013), 2511–2521.
165. Kim, H., Jang, J.H., Kim, S.C., Cho, J.H., De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. J. Antimicrob. Chemother. 69 (2014), 121–132.
166. Tillotson, G.S., Theriault, N., New and alternative approaches to tackling antibiotic resistance. F1000Prime Rep., 5, 2013, 51.
167. Findlay, B., Zhanel, G.G., Schweizer, F., Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob. Agents Chemother. 54 (2010), 4049–4058.
168. Rotem, S., Mor, A., Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788 (2009), 1582–1592.
169. Pag, U., Oedenkoven, M., Papo, N., Oren, Z., Shai, Y., Sahl, H.G., In vitro activity and mode of action of diastereomeric antimicrobial peptides against bacterial clinical isolates. J. Antimicrob. Chemother. 53 (2004), 230–239.
170. Chen, Y., Vasil, A.I., Rehaume, L., Mant, C.T., Burns, J.L., Vasil, M.L., Hancock, R.E., Hodges, R.S., Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides. Chem. Biol. Drug Des. 67 (2006), 162–173.
171. de la Fuente-Nunez, C., Reffuveille, F., Mansour, S.C., Reckseidler-Zenteno, S.L., Hernandez, D., Brackman, G., Coenye, T., Hancock, R.E., D-Enantiomeric peptides that eradicate wild-type and multidrug-resistant biofilms and protect against lethal Pseudomonas aeruginosa infections. Chem. Biol. 22 (2015), 196–205.
172. Marsh, E.N., Buer, B.C., Ramamoorthy, A., Fluorine—a new element in the design of membrane-active peptides. Mol. BioSyst. 5 (2009), 1143–1147.
173. Meng, H., Kumar, K., Antimicrobial activity and protease stability of peptides containing fluorinated amino acids. J. Am. Chem. Soc. 129 (2007), 15615–15622.
174. Gimenez, D., Andreu, C., del Olmo, M., Varea, T., Diaz, D., Asensio, G., The introduction of fluorine atoms or trifluoromethyl groups in short cationic peptides enhances their antimicrobial activity. Bioorg. Med. Chem. 14 (2006), 6971–6978.
175. Huang, M.L., Shin, S.B., Benson, M.A., Torres, V.J., Kirshenbaum, K., A comparison of linear and cyclic peptoid oligomers as potent antimicrobial agents. ChemMedChem 7 (2012), 114–122.
176. Kapoor, R., Wadman, M.W., Dohm, M.T., Czyzewski, A.M., Spormann, A.M., Barron, A.E., Antimicrobial peptoids are effective against Pseudomonas aeruginosa biofilms. Antimicrob. Agents Chemother. 55 (2011), 3054–3057.
177. Raguse, T.L., Porter, E.A., Weisblum, B., Gellman, S.H., Structure–activity studies of 14-helical antimicrobial beta-peptides: probing the relationship between conformational stability and antimicrobial potency. J. Am. Chem. Soc. 124 (2002), 12774–12785.
178. Porter, E.A., Weisblum, B., Gellman, S.H., Mimicry of host-defense peptides by unnatural oligomers: antimicrobial beta-peptides. J. Am. Chem. Soc. 124 (2002), 7324–7330.
179. Olsen, C.A., Ziegler, H.L., Nielsen, H.M., Frimodt-Moller, N., Jaroszewski, J.W., Franzyk, H., Antimicrobial, hemolytic, and cytotoxic activities of beta-peptoid-peptide hybrid oligomers: improved properties compared to natural AMPs. Chembiochem 11 (2010), 1356–1360.
180. Ryge, T.S., Frimodt-Moller, N., Hansen, P.R., Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi. Chemotherapy 54 (2008), 152–156.
181. Chu-Kung, A.F., Bozzelli, K.N., Lockwood, N.A., Haseman, J.R., Mayo, K.H., Tirrell, M.V., Promotion of peptide antimicrobial activity by fatty acid conjugation. Bioconjug. Chem. 15 (2004), 530–535.
182. Laverty, G., McLaughlin, M., Shaw, C., Gorman, S.P., Gilmore, B.F., Antimicrobial activity of short, synthetic cationic lipopeptides. Chem. Biol. Drug Des. 75 (2010), 563–569.
183. Makovitzki, A., Avrahami, D., Shai, Y., Ultrashort antibacterial and antifungal lipopeptides. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 15997–16002.
184. Makovitzki, A., Baram, J., Shai, Y., Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 47 (2008), 10630–10636.
185. Chongsiriwatana, N.P., Miller, T.M., Wetzler, M., Vakulenko, S., Karlsson, A.J., Palecek, S.P., Mobashery, S., Barron, A.E., Short alkylated peptoid mimics of antimicrobial lipopeptides. Antimicrob. Agents Chemother. 55 (2011), 417–420.
186. Bucki, R., Niemirowicz, K., Wnorowska, U., Byfield, F.J., Piktel, E., Watek, M., Janmey, P.A., Savage, P.B., Bactericidal activity of ceragenin CSA-13 in cell culture and in an animal model of peritoneal infection. Antimicrob. Agents Chemother. 59 (2015), 6274–6282.
187. Lai, X.Z., Feng, Y., Pollard, J., Chin, J.N., Rybak, M.J., Bucki, R., Epand, R.F., Epand, R.M., Savage, P.B., Ceragenins: cholic acid-based mimics of antimicrobial peptides. Acc. Chem. Res. 41 (2008), 1233–1240.
188. Chin, J.N., Rybak, M.J., Cheung, C.M., Savage, P.B., Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 51 (2007), 1268–1273.
189. Nagant, C., Pitts, B., Stewart, P.S., Feng, Y., Savage, P.B., Dehaye, J.P., Study of the effect of antimicrobial peptide mimic, CSA-13, on an established biofilm formed by Pseudomonas aeruginosa. Microbiologyopen 2 (2013), 318–325.
190. Bower, C.K., Parker, J.E., Higgins, A.Z., Oest, M.E., Wilson, J.T., Valentine, B.A., Bothwell, M.K., McGuire, J., Protein antimicrobial barriers to bacterial adhesion: in vitro and in vivo evaluation of nisin-treated implantable materials. Colloids Surf. B: Biointerfaces 25 (2002), 81–90.
191. Cheigh, C.I., Pyun, Y.R., Nisin biosynthesis and its properties. Biotechnol. Lett. 27 (2005), 1641–1648.
192. Sinclair, K.D., Pham, T.X., Williams, D.L., Farnsworth, R.W., Loc-Carrillo, C.M., Bloebaum, R.D., Model development for determining the efficacy of a combination coating for the prevention of perioperative device related infections: a pilot study. J. Biomed. Mater. Res. B Appl. Biomater. 101 (2013), 1143–1153.
193. Minardi, D., Ghiselli, R., Cirioni, O., Giacometti, A., Kamysz, W., Orlando, F., Silvestri, C., Parri, G., Kamysz, E., Scalise, G., Saba, V., Giovanni, M., The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model. Peptides 28 (2007), 2293–2298.
194. Stallmann, H.P., Faber, C., Bronckers, A.L., Nieuw Amerongen, A.V., Wuisman, P.I., Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11- or gentamicin-containing calcium phosphate cement. J. Antimicrob. Chemother. 54 (2004), 472–476.